论文部分内容阅读
Gefitinib is widely used for the treatment of lung cancer in patients with sensitizing epidermal growth factor receptor mutations, but patients tend to develop resistance after an average of 10 months.Low molecular weight heparins, such as enoxaparin, potently inhibit experimental metastasis.